Amgen (AMGN) 174.80 $AMGN FDA Approves Amgen's
Post# of 273254
Posted On: 09/24/2016 5:15:15 AM
Amgen (AMGN) 174.80 $AMGN
FDA Approves Amgen's AMJEVITA(TM) (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases
PR Newswire - Fri Sep 23, 5:04PM CDT
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AMJEVITA(TM) (adalimumab-atto) across all eligible indications of the reference product, Humira® (adalimumab). AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaque psoriasis, adult moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis. AMJEVITA is Amgen's first biosimilar to receive regulatory approval.
AMGN: 174.80 (-0.82)
FDA approves lower-cost alternative to biotech drug Humira
AP - Fri Sep 23, 4:31PM CDT
WASHINGTON (AP) — Federal regulators have approved the first alternative version of the second-biggest selling drug in the world, AbbVie's Humira, a blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.
AMGN: 174.80 (-0.82)
Rheumatoid Arthritis Market 2016 Dynamics and 2020 Forecasts
PR Newswire - Wed Sep 21, 11:45AM CDT
The Global Rheumatoid Arthritis Market Report: 2016 Edition research of 47 pages providing profiles of 4 leading companies is supported with 28 Charts as well as 8 data tables and is now available in the pharmaceuticals industry segment of MarketReportsOnline.com.
AMGN: 174.80 (-0.82)
Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:47AM CDT
Amgen, Inc. (AMGN) announced positive top-line results from a phase III study evaluating the effect of its cholesterol-lowering medication, Repatha (evolocumab) on coronary artery disease (CAD) patients.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), AMGN: 174.80 (-0.82), ANIK: 46.92 (-1.07)
Stock Market News for September 21, 2016
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:22AM CDT
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
FDX: 174.39 (+0.73), AGN: 243.94 (+0.51), PBR: 9.18 (-0.38), BIIB: 312.58 (-2.23), SON: 52.89 (-0.61), GILD: 81.37 (-0.15), FB: 127.96 (-2.12), XOM: 83.45 (-0.09), AMGN: 174.80 (-0.82), KBH: 15.70 (+0.05), TBRA: 39.11 (-0.39)
Global Musculoskeletal Disorders Therapeutics Market 2016-2020 with AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche & Eli Lilly Dominating - Research and Markets
BusinessWire - Wed Sep 21, 9:19AM CDT
Research and Markets has announced the addition of the "Global Musculoskeletal Disorders Therapeutics Market 2016-2020" report to their offering.
JNJ: 118.81 (-0.65), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13)
Keryx's Supply Interruption Of Auryxia And The Delayed Approval For Amgen's Parsabiv Shake Things Up In The Renal Market
PR Newswire - Tue Sep 20, 2:07PM CDT
While nephrologists are stating that the recent supply interruption of Keryx's phosphate binder, Auryxia, does not have a major impact on their practice, the challenge for Keryx will be the re-build - 48% of the nephrologists that had patients on Auryxia, anticipate a slow uptake once supply has been restored with only 6% predicting a rapid expansion. The majority of previous non-users do not plan to use Auryxia once supply is restored. This represents an opportunity for Vifor-FMC's Velphoro and Sanofi's Renvela to capture Auryxia patients who do not have ample supply to bridge the interruption.
AMGN: 174.80 (-0.82)
After Yesterday's Rally of 1.40% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Sep 20, 12:08PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $172.46 to a high of $174.18. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $173.50 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 174.80 (-0.82)
Watch for Amgen to Potentially Pullback After Gaining 1.40% Yesterday
Comtex SmarTrend(R) - Tue Sep 20, 12:07PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $172.46 to a high of $174.18. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $173.50 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 174.80 (-0.82)
Amgen (AMGN) Crosses Pivot Point Resistance at $172.86
Comtex SmarTrend(R) - Tue Sep 20, 8:45AM CDT
Amgen (NASDAQ:AMGN) has opened bullishly above the pivot of $172.02 today and has reached the first level of resistance at $172.86. Investors may be interested in a cross of the next upside pivot targets of $174.34 and $176.66.
AMGN: 174.80 (-0.82)
Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)
PR Newswire - Tue Sep 20, 8:00AM CDT
Amgen (NASDAQ:AMGN) today announced that the Phase 3 GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound) trial evaluating the effect of Repatha® (evolocumab) on coronary artery disease (CAD) met its primary and secondary endpoints. The GLAGOV study is a large serial coronary intravascular imaging trial designed to test whether treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha modifies atherosclerotic plaque build-up in the coronary arteries of patients already treated with optimized statin therapy.
AMGN: 174.80 (-0.82)
Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 9:38AM CDT
Amgen, Inc.'s (AMGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for its pipeline secondary hyperparathyroidism (SHPT) candidate Parsabiv (etelcalcetide).
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), AMGN: 174.80 (-0.82)
Insider Q&A: Why so little relief on pricey biologic drugs
By LINDA A. JOHNSON - AP - Sun Sep 18, 1:01PM CDT
Drugs made from living cells, instead of by mixing chemicals, have brought major advances since the late 1990s to the treatment of various cancers, immune system disorders, growth hormone deficiency and eye diseases.
JNJ: 118.81 (-0.65), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82)
Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
PR Newswire - Sun Sep 18, 10:00AM CDT
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced findings from the FRAME study showing that the investigational agent romosozumab significantly reduced the incidence of new vertebral fractures in postmenopausal women with osteoporosis through 12 and 24 months, meeting the study's co-primary endpoints. The results from the Phase 3 study, the first to evaluate fracture risk reduction as early as one year as a primary endpoint, were published in the New England Journal of Medicine (NEJM) and presented today in an oral session at the Annual Meeting of the American Society for Bone Mineral Research (ASBMR) in Atlanta. Romosozumab works by binding and inhibiting the activity of the protein sclerostin, and as a result, has a dual effect on bone, both increasing bone formation and decreasing bone breakdown.
AMGN: 174.80 (-0.82)
InvestorsObserver releases covered-call reports for Alder Biopharmaceuticals, bluebird bio Inc., Expedia, Amgen and Computer Sciences Corporation
PR Newswire - Fri Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ALDR, AMGN, BLUE, CSC, and EXPE.
BLUE: 71.68 (-1.62), ALDR: 33.97 (-0.33), CSC: 51.57 (-0.30), EXPE: 109.91 (+1.12), AMGN: 174.80 (-0.82)
Novartis Reports Positive Phase II Data on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:21AM CDT
Novartis AG (NVS) announced results from a phase II study on migraine candidate AMG 334.
LGND: 115.78 (-2.38), AMGN: 174.80 (-0.82), PCRX: 36.86 (-0.66), NVS: 81.48 (-0.55)
Research Reports on Biotech Equities -- Galena Biopharma, Mast Therapeutics, Medivation, and Amgen
PR Newswire - Fri Sep 16, 6:35AM CDT
The Biotech industry registered strong gains on Monday, September 12, 2016, with every ETF in the green. Driving stocks higher were surges in M&A deals, dovish comments made by the Fed on policy tightening, and Trump's rising tracking poll results. Today, Stock-Callers.com reviews four equities to see how they fared over the last few trading sessions: Galena Biopharma Inc. (NASDAQ: GALE), Mast Therapeutics Inc. (NYSE MKT: MSTX), Medivation Inc. (NASDAQ: MDVN), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free research reports at: http://stock-callers.com/registration
MDVN: 81.42 (+0.34), MSTX: 0.13 (unch), AMGN: 174.80 (-0.82), GALE: 0.36 (-0.01)
Amgen Receives Positive CHMP Opinion For Parsabiv(TM) (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis
PR Newswire - Fri Sep 16, 6:34AM CDT
Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of Parsabiv(TM) (etelcalcetide), recommending approval for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. If approved, Parsabiv will be the first calcimimetic agent that can be administered intravenously by a healthcare provider three times a week at the end of a hemodialysis session.
AMGN: 174.80 (-0.82)
Dr. Reddy's Expands Strategic Collaboration with Amgen in India
BusinessWire - Fri Sep 16, 5:54AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that it has expanded its strategic collaboration with Amgen, one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis. Under the terms of the collaboration, Dr. Reddy's will commercialise XGEVA(R) (denosumab), Vectibix(R) (panitumumab) and Prolia(R) (denosumab) in India.
AMGN: 174.80 (-0.82), RDY: 47.90 (+0.20)
Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine
PR Newswire - Thu Sep 15, 3:30PM CDT
Amgen (NASDAQ:AMGN) today announced detailed global Phase 2 results showing erenumab demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. The data will be presented in posters #P057 and #P058 at the 5th European Headache and Migraine Trust International Congress (EHMTIC) in Glasgow, Scotland.
AMGN: 174.80 (-0.82)
FDA Approves Amgen's AMJEVITA(TM) (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases
PR Newswire - Fri Sep 23, 5:04PM CDT
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AMJEVITA(TM) (adalimumab-atto) across all eligible indications of the reference product, Humira® (adalimumab). AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaque psoriasis, adult moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis. AMJEVITA is Amgen's first biosimilar to receive regulatory approval.
AMGN: 174.80 (-0.82)
FDA approves lower-cost alternative to biotech drug Humira
AP - Fri Sep 23, 4:31PM CDT
WASHINGTON (AP) — Federal regulators have approved the first alternative version of the second-biggest selling drug in the world, AbbVie's Humira, a blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.
AMGN: 174.80 (-0.82)
Rheumatoid Arthritis Market 2016 Dynamics and 2020 Forecasts
PR Newswire - Wed Sep 21, 11:45AM CDT
The Global Rheumatoid Arthritis Market Report: 2016 Edition research of 47 pages providing profiles of 4 leading companies is supported with 28 Charts as well as 8 data tables and is now available in the pharmaceuticals industry segment of MarketReportsOnline.com.
AMGN: 174.80 (-0.82)
Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:47AM CDT
Amgen, Inc. (AMGN) announced positive top-line results from a phase III study evaluating the effect of its cholesterol-lowering medication, Repatha (evolocumab) on coronary artery disease (CAD) patients.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), AMGN: 174.80 (-0.82), ANIK: 46.92 (-1.07)
Stock Market News for September 21, 2016
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:22AM CDT
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
FDX: 174.39 (+0.73), AGN: 243.94 (+0.51), PBR: 9.18 (-0.38), BIIB: 312.58 (-2.23), SON: 52.89 (-0.61), GILD: 81.37 (-0.15), FB: 127.96 (-2.12), XOM: 83.45 (-0.09), AMGN: 174.80 (-0.82), KBH: 15.70 (+0.05), TBRA: 39.11 (-0.39)
Global Musculoskeletal Disorders Therapeutics Market 2016-2020 with AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche & Eli Lilly Dominating - Research and Markets
BusinessWire - Wed Sep 21, 9:19AM CDT
Research and Markets has announced the addition of the "Global Musculoskeletal Disorders Therapeutics Market 2016-2020" report to their offering.
JNJ: 118.81 (-0.65), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13)
Keryx's Supply Interruption Of Auryxia And The Delayed Approval For Amgen's Parsabiv Shake Things Up In The Renal Market
PR Newswire - Tue Sep 20, 2:07PM CDT
While nephrologists are stating that the recent supply interruption of Keryx's phosphate binder, Auryxia, does not have a major impact on their practice, the challenge for Keryx will be the re-build - 48% of the nephrologists that had patients on Auryxia, anticipate a slow uptake once supply has been restored with only 6% predicting a rapid expansion. The majority of previous non-users do not plan to use Auryxia once supply is restored. This represents an opportunity for Vifor-FMC's Velphoro and Sanofi's Renvela to capture Auryxia patients who do not have ample supply to bridge the interruption.
AMGN: 174.80 (-0.82)
After Yesterday's Rally of 1.40% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Sep 20, 12:08PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $172.46 to a high of $174.18. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $173.50 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 174.80 (-0.82)
Watch for Amgen to Potentially Pullback After Gaining 1.40% Yesterday
Comtex SmarTrend(R) - Tue Sep 20, 12:07PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $172.46 to a high of $174.18. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $173.50 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 174.80 (-0.82)
Amgen (AMGN) Crosses Pivot Point Resistance at $172.86
Comtex SmarTrend(R) - Tue Sep 20, 8:45AM CDT
Amgen (NASDAQ:AMGN) has opened bullishly above the pivot of $172.02 today and has reached the first level of resistance at $172.86. Investors may be interested in a cross of the next upside pivot targets of $174.34 and $176.66.
AMGN: 174.80 (-0.82)
Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)
PR Newswire - Tue Sep 20, 8:00AM CDT
Amgen (NASDAQ:AMGN) today announced that the Phase 3 GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound) trial evaluating the effect of Repatha® (evolocumab) on coronary artery disease (CAD) met its primary and secondary endpoints. The GLAGOV study is a large serial coronary intravascular imaging trial designed to test whether treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha modifies atherosclerotic plaque build-up in the coronary arteries of patients already treated with optimized statin therapy.
AMGN: 174.80 (-0.82)
Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 9:38AM CDT
Amgen, Inc.'s (AMGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for its pipeline secondary hyperparathyroidism (SHPT) candidate Parsabiv (etelcalcetide).
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), AMGN: 174.80 (-0.82)
Insider Q&A: Why so little relief on pricey biologic drugs
By LINDA A. JOHNSON - AP - Sun Sep 18, 1:01PM CDT
Drugs made from living cells, instead of by mixing chemicals, have brought major advances since the late 1990s to the treatment of various cancers, immune system disorders, growth hormone deficiency and eye diseases.
JNJ: 118.81 (-0.65), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82)
Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
PR Newswire - Sun Sep 18, 10:00AM CDT
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced findings from the FRAME study showing that the investigational agent romosozumab significantly reduced the incidence of new vertebral fractures in postmenopausal women with osteoporosis through 12 and 24 months, meeting the study's co-primary endpoints. The results from the Phase 3 study, the first to evaluate fracture risk reduction as early as one year as a primary endpoint, were published in the New England Journal of Medicine (NEJM) and presented today in an oral session at the Annual Meeting of the American Society for Bone Mineral Research (ASBMR) in Atlanta. Romosozumab works by binding and inhibiting the activity of the protein sclerostin, and as a result, has a dual effect on bone, both increasing bone formation and decreasing bone breakdown.
AMGN: 174.80 (-0.82)
InvestorsObserver releases covered-call reports for Alder Biopharmaceuticals, bluebird bio Inc., Expedia, Amgen and Computer Sciences Corporation
PR Newswire - Fri Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ALDR, AMGN, BLUE, CSC, and EXPE.
BLUE: 71.68 (-1.62), ALDR: 33.97 (-0.33), CSC: 51.57 (-0.30), EXPE: 109.91 (+1.12), AMGN: 174.80 (-0.82)
Novartis Reports Positive Phase II Data on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:21AM CDT
Novartis AG (NVS) announced results from a phase II study on migraine candidate AMG 334.
LGND: 115.78 (-2.38), AMGN: 174.80 (-0.82), PCRX: 36.86 (-0.66), NVS: 81.48 (-0.55)
Research Reports on Biotech Equities -- Galena Biopharma, Mast Therapeutics, Medivation, and Amgen
PR Newswire - Fri Sep 16, 6:35AM CDT
The Biotech industry registered strong gains on Monday, September 12, 2016, with every ETF in the green. Driving stocks higher were surges in M&A deals, dovish comments made by the Fed on policy tightening, and Trump's rising tracking poll results. Today, Stock-Callers.com reviews four equities to see how they fared over the last few trading sessions: Galena Biopharma Inc. (NASDAQ: GALE), Mast Therapeutics Inc. (NYSE MKT: MSTX), Medivation Inc. (NASDAQ: MDVN), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free research reports at: http://stock-callers.com/registration
MDVN: 81.42 (+0.34), MSTX: 0.13 (unch), AMGN: 174.80 (-0.82), GALE: 0.36 (-0.01)
Amgen Receives Positive CHMP Opinion For Parsabiv(TM) (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis
PR Newswire - Fri Sep 16, 6:34AM CDT
Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of Parsabiv(TM) (etelcalcetide), recommending approval for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. If approved, Parsabiv will be the first calcimimetic agent that can be administered intravenously by a healthcare provider three times a week at the end of a hemodialysis session.
AMGN: 174.80 (-0.82)
Dr. Reddy's Expands Strategic Collaboration with Amgen in India
BusinessWire - Fri Sep 16, 5:54AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that it has expanded its strategic collaboration with Amgen, one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis. Under the terms of the collaboration, Dr. Reddy's will commercialise XGEVA(R) (denosumab), Vectibix(R) (panitumumab) and Prolia(R) (denosumab) in India.
AMGN: 174.80 (-0.82), RDY: 47.90 (+0.20)
Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine
PR Newswire - Thu Sep 15, 3:30PM CDT
Amgen (NASDAQ:AMGN) today announced detailed global Phase 2 results showing erenumab demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. The data will be presented in posters #P057 and #P058 at the 5th European Headache and Migraine Trust International Congress (EHMTIC) in Glasgow, Scotland.
AMGN: 174.80 (-0.82)
(0)
(0)Scroll down for more posts ▼